Cargando…
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3 or NS5A detected in samples from HCV genotype 1-i...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163913/ https://www.ncbi.nlm.nih.gov/pubmed/30154359 http://dx.doi.org/10.3390/v10090462 |
_version_ | 1783359475319570432 |
---|---|
author | Ng, Teresa I. Pilot-Matias, Tami Tripathi, Rakesh Schnell, Gretja Krishnan, Preethi Reisch, Thomas Beyer, Jill Dekhtyar, Tatyana Irvin, Michelle Lu, Liangjun Asatryan, Armen Campbell, Andrew Yao, Betty Lovell, Sandra Mensa, Federico Lawitz, Eric J. Kort, Jens Collins, Christine |
author_facet | Ng, Teresa I. Pilot-Matias, Tami Tripathi, Rakesh Schnell, Gretja Krishnan, Preethi Reisch, Thomas Beyer, Jill Dekhtyar, Tatyana Irvin, Michelle Lu, Liangjun Asatryan, Armen Campbell, Andrew Yao, Betty Lovell, Sandra Mensa, Federico Lawitz, Eric J. Kort, Jens Collins, Christine |
author_sort | Ng, Teresa I. |
collection | PubMed |
description | Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3 or NS5A detected in samples from HCV genotype 1-infected patients receiving 3-day monotherapy of glecaprevir or pibrentasvir, respectively. None of the NS3 polymorphisms detected in the 47 baseline samples collected prior to glecaprevir monotherapy conferred reduced susceptibility to glecaprevir. The NS3 A156T substitution, which conferred resistance to glecaprevir but had low replication efficiency, emerged in one genotype 1a-infected patient among the 35 patients with available post-baseline sequence data. Baseline NS5A polymorphisms were detected in 12 of 40 patients prior to pibrentasvir monotherapy; most polymorphisms were single-position NS5A amino acid substitutions that did not confer resistance to pibrentasvir. Among the 19 patients with available post-baseline NS5A sequence data, 3 had treatment-emergent NS5A substitutions during pibrentasvir monotherapy. All treatment-emergent NS5A substitutions were linked multiple-position, almost exclusively double-position, substitutions that conferred resistance to pibrentasvir. Replicons engineered with these double-position substitutions had low replication efficiency. In conclusion, resistance-conferring substitutions emerged in a small number of genotype 1-infected patients during glecaprevir or pibrentasvir monotherapy; unlike other NS5A inhibitors, pibrentasvir did not select single-position NS5A substitutions during monotherapy. |
format | Online Article Text |
id | pubmed-6163913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61639132018-10-11 Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection Ng, Teresa I. Pilot-Matias, Tami Tripathi, Rakesh Schnell, Gretja Krishnan, Preethi Reisch, Thomas Beyer, Jill Dekhtyar, Tatyana Irvin, Michelle Lu, Liangjun Asatryan, Armen Campbell, Andrew Yao, Betty Lovell, Sandra Mensa, Federico Lawitz, Eric J. Kort, Jens Collins, Christine Viruses Article Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3 or NS5A detected in samples from HCV genotype 1-infected patients receiving 3-day monotherapy of glecaprevir or pibrentasvir, respectively. None of the NS3 polymorphisms detected in the 47 baseline samples collected prior to glecaprevir monotherapy conferred reduced susceptibility to glecaprevir. The NS3 A156T substitution, which conferred resistance to glecaprevir but had low replication efficiency, emerged in one genotype 1a-infected patient among the 35 patients with available post-baseline sequence data. Baseline NS5A polymorphisms were detected in 12 of 40 patients prior to pibrentasvir monotherapy; most polymorphisms were single-position NS5A amino acid substitutions that did not confer resistance to pibrentasvir. Among the 19 patients with available post-baseline NS5A sequence data, 3 had treatment-emergent NS5A substitutions during pibrentasvir monotherapy. All treatment-emergent NS5A substitutions were linked multiple-position, almost exclusively double-position, substitutions that conferred resistance to pibrentasvir. Replicons engineered with these double-position substitutions had low replication efficiency. In conclusion, resistance-conferring substitutions emerged in a small number of genotype 1-infected patients during glecaprevir or pibrentasvir monotherapy; unlike other NS5A inhibitors, pibrentasvir did not select single-position NS5A substitutions during monotherapy. MDPI 2018-08-28 /pmc/articles/PMC6163913/ /pubmed/30154359 http://dx.doi.org/10.3390/v10090462 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ng, Teresa I. Pilot-Matias, Tami Tripathi, Rakesh Schnell, Gretja Krishnan, Preethi Reisch, Thomas Beyer, Jill Dekhtyar, Tatyana Irvin, Michelle Lu, Liangjun Asatryan, Armen Campbell, Andrew Yao, Betty Lovell, Sandra Mensa, Federico Lawitz, Eric J. Kort, Jens Collins, Christine Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection |
title | Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection |
title_full | Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection |
title_fullStr | Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection |
title_full_unstemmed | Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection |
title_short | Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection |
title_sort | resistance analysis of a 3-day monotherapy study with glecaprevir or pibrentasvir in patients with chronic hepatitis c virus genotype 1 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163913/ https://www.ncbi.nlm.nih.gov/pubmed/30154359 http://dx.doi.org/10.3390/v10090462 |
work_keys_str_mv | AT ngteresai resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT pilotmatiastami resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT tripathirakesh resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT schnellgretja resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT krishnanpreethi resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT reischthomas resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT beyerjill resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT dekhtyartatyana resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT irvinmichelle resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT luliangjun resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT asatryanarmen resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT campbellandrew resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT yaobetty resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT lovellsandra resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT mensafederico resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT lawitzericj resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT kortjens resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection AT collinschristine resistanceanalysisofa3daymonotherapystudywithglecaprevirorpibrentasvirinpatientswithchronichepatitiscvirusgenotype1infection |